Interpreting and Reporting F-18 PET MPI: Focus on Flurpiridaz Cases-Interpreting and Reporting F-18 PET MPI: A Focus on Flurpiridaz Cases

Video Transcription

Video Summary

The webinar hosted by the American Society of Nuclear Cardiology focused on interpreting and reporting F18 PET and PI with an emphasis on Flurpiridaz cases. Co-chaired by Dr. Moaz Al-Mallah and Dr. Panetia Shirintuwati, it featured experts like Dr. Marcella DeCarli, Dr. Shamshid Medahi, Dr. Peter Slomka, and Dr. Jennifer Renaud. The session aimed to educate participants on acquisition protocols, interpretation, and reporting of F18 cardiac PET tracers. It emphasized understanding physiologic uptake patterns, incidental findings, and methodologic approaches to review these images. <br /><br />The webinar highlighted the importance of quality assurance in PET CT imaging and the need to ensure proper alignment to avoid artifacts. Speakers discussed the nuances of different tracers like Flurpiridaz, including its advantages such as high image quality and its potential drawbacks like exposure to higher radiation doses. A significant portion of the session was dedicated to interpreting cases and identifying abnormalities using the new tracer. <br /><br />Key insights included the importance of recognizing normal variants like apical thinning and papillary muscle visibility, understanding the impact of tracer pharmacokinetics, and utilizing flow data for diagnosis and prognosis. The session concluded with a strong emphasis on continuous learning as Flurpiridaz is integrated into clinical practice, noting the need for diligence in technical execution and ongoing professional education to maximize the tracer's potential clinical benefits.

Keywords

American Society of Nuclear Cardiology

F18 PET

Flurpiridaz

cardiac imaging

quality assurance

PET CT imaging

tracer pharmacokinetics

interpretation

acquisition protocols

physiologic uptake patterns

artifacts

clinical practice

professional education